Advances in Cancer Vaccine Research

Liu, Nian; Xiao, Xiangyu; Zhang, Ziqiang; Mao, Chun; Wan, Mimi; Shen, Jian

doi:10.1021/acsbiomaterials.3c01154

Cited by 8 publications

(4 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given its preferential expression in cancer cells, it is an attractive target for immunotherapy approaches, such as cancer vaccines or Chimeric Antigen Receptor T-cell (CAR-T) therapies [30,31]. These strategies aim to train the immune system to recognise and destroy cells expressing PRAME, sparing normal tissues that do not express the antigen or express it at low levels [32,33]. Several clinical trials are underway trying to exploit CTAs, including PRAME, for cancer treatment.…”

Section: Prame and Cancermentioning

confidence: 99%

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Cassalia,

Danese,

Tudurachi

et al. 2024

IJMS

View full text Add to dashboard Cite

Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a nuclear receptor and transcriptional regulator, PRAME plays a critical role in inhibiting retinoic acid signalling, which is essential for cell differentiation and proliferation. Its aberrant overexpression in various malignancies, particularly cutaneous melanoma, is associated with more aggressive tumour phenotypes, positioning PRAME as both a diagnostic and prognostic marker. In melanoma, PRAME is typically highly expressed, in contrast to its weak or absent expression in benign nevi, thereby improving the accuracy of differential diagnoses. The diagnostic value of PRAME extends to various lesions. It is significantly expressed in uveal melanoma, correlating to an increased risk of metastasis. In acral melanomas, especially those with histopathological ambiguity, PRAME helps to improve diagnostic accuracy. However, its expression in spitzoid and ungual melanocytic lesions is inconsistent and requires a comprehensive approach for an accurate assessment. In soft tissue sarcomas, PRAME may be particularly helpful in differentiating melanoma from clear cell sarcoma, an important distinction due to their similar histological appearance but different treatment approaches and prognosis, or in detecting dedifferentiated and undifferentiated melanomas. In non-melanoma skin cancers such as basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma, the variable expression of PRAME can lead to diagnostic complexity. Despite these challenges, the potential of PRAME as a therapeutic target in melanoma is significant. Emerging immunotherapies, including T-cell-based therapies and vaccines targeting PRAME, are being investigated to exploit its cancer-specific expression. Ongoing research into the molecular role and mechanism of action of PRAME in skin cancer continues to open new avenues in both diagnostics and therapeutics, with the potential to transform the management of melanoma and related skin cancers.

show abstract

Section: Prame and Cancermentioning

confidence: 99%

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Cassalia,

Danese,

Tudurachi

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Notably, the clinical benefit is limited to a fraction of patients 3 . Immunotherapy has been adopted in a variety of malignancy like breast cancer (BC), lung cancer, hepatocarcinoma, and melanoma 4 . However, some patients do not respond well to immunotherapy, especially for those with low immunogenicity, which means that the tumors are not easily recognized and targeted by the immune system 5 .…”

Section: Introductionmentioning

confidence: 99%

“… 3 Immunotherapy has been adopted in a variety of malignancy like breast cancer (BC), lung cancer, hepatocarcinoma, and melanoma. 4 However, some patients do not respond well to immunotherapy, especially for those with low immunogenicity, which means that the tumors are not easily recognized and targeted by the immune system. 5 Additionally, the tumor microenvironment can be immunosuppressive, further hindering the effectiveness of immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications

Wang,

et al. 2024

MedComm

View full text Add to dashboard Cite

Cancer is a major cause of death globally, and traditional treatments often have limited efficacy and adverse effects. Immunotherapy has shown promise in various malignancies but is less effective in tumors with low immunogenicity or immunosuppressive microenvironment, especially sarcomas. Tertiary lymphoid structures (TLSs) have been associated with a favorable response to immunotherapy and improved survival in cancer patients. However, the immunological mechanisms and clinical significance of TLS in malignant tumors are not fully understood. In this review, we elucidate the composition, neogenesis, and immune characteristics of TLS in tumors, as well as the inflammatory response in cancer development. An in‐depth discussion of the unique immune characteristics of TLSs in lung cancer, breast cancer, melanoma, and soft tissue sarcomas will be presented. Additionally, the therapeutic implications of TLS, including its role as a marker of therapeutic response and prognosis, and strategies to promote TLS formation and maturation will be explored. Overall, we aim to provide a comprehensive understanding of the role of TLS in the tumor immune microenvironment and suggest potential interventions for cancer treatment.

show abstract

“…These vaccines aim to overcome tumor heterogeneity and reverse the immunosuppressive microenvironment. Challenges in the field include single antigen targeting, weak immunogenicity, off-target effects, and impaired immune response [ 25 – 27 ]. Current research and reviews provide insights into the principle of action, components, classification, delivery methods, and progress of cancer vaccines, offering a broader perspective for future vaccine design.…”

Section: Introductionmentioning

confidence: 99%

Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective

Wu,

2024

IET Nanobiotechnology

View full text Add to dashboard Cite

Cancer vaccines based on tumor cell components have shown promising results in animal and clinical studies. The vaccine system contains abundant tumor antigen components, which can activate the immune system by antigens. However, their efficacy has been limited by the inability of antigens delivery, which are the core components of vaccines, further fail to be presented and activation of effective cells. Nanotechnology offers a novel platform to enhance the immunogenicity of tumor-associated antigens and deliver them to antigen-presenting cells (APCs) more efficiently. In addition, nanotreatment of tumor cells derivate active ingredients could also help improve the effectiveness of cancer vaccines. In this review, we summarize recent advances in the development of cancer vaccines by the combination of nanotechnology and tumor-based ingredients, including liposomes, polymeric nanoparticles, metallic nanoparticles, virus-like particles and tumor cells membrane, tumor lysate, and specific tumor antigens. These nanovaccines have been designed to increase antigen uptake, prolong antigen presentation, and modulate immune responses through codelivery of immunostimulatory agents. We also further discuss challenges and opportunities in the clinical translation of these nanovaccines.

show abstract

Advances in Cancer Vaccine Research

Cited by 8 publications

References 230 publications

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer

Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications

Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective

Contact Info

Product

Resources

About